Skip to main content

Market Overview

18 Biggest Mid-Day Gainers For Wednesday

  • Orexigen Therapeutics, Inc. (NASDAQ: OREX) shares surged 44.3 percent to $2.99 after the company announced a new ad campaign that will launch this week called 'Brains Behind Weight Loss'.
  • CymaBay Therapeutics Inc (NASDAQ: CBAY) shares climbed 33.7 percent to $2.54 after the company reported a licensing deal with Kowa Pharmaceuticals America, Inc. for exclusive US rights to arhalofenate.
  • Evoke Pharma Inc (NASDAQ: EVOK) shares jumped 27 percent to $2.63. Evoke Pharma disclosed that Phase 3 Gimoti trial failed to reach its primary endpoint. However, the company announced that 51 percent of patients responded better to Gimoti than placebo.
  • Merus NV (NASDAQ: MRUS) shares gained 22.9 percent to $25.90.
  • PhotoMedex Inc (NASDAQ: PHMD) shares rose 22.1 percent to $2.97. PhotoMedex shares have increased 10.45 percent over the past 52 weeks, while the S&P 500 index has gained 12.18 percent in the same period.
  • O2Micro International Limited (ADR) (NASDAQ: OIIM) shares surged 21.5 percent to $2.30 after the company revised its Q4 financial guidance. O2Micro raised its Q4 revenue guidance from $14.7 million-$15.6 million to $15.4 million-$15.9 million.
  • Weight Watchers International, Inc. (NYSE: WTW) climbed 19.2 percent to $13.21.
  • ImmunoGen, Inc. (NASDAQ: IMGN) shares rose 18 percent to $2.45 after gaining 1.96 percent on Tuesday.
  • Shake Shack Inc (NYSE: SHAK) gained 7.7 percent to $38.90. Shake Shack will replace Chemours in the S&P SmallCap 600 after the close of trading on January 4.
  • Partner Communications Company Ltd (ADR) (NASDAQ: PTNR) shares rose 6.8 percent to $5.43 after gaining 8.42 percent on Tuesday.
  • Encana Corp (USA) (NYSE: ECA) shares rose 6.2 percent to $12.68 in pre-market trading. Ecana is expecting 2017 corporate margin to be greater than $10 per barrel of oil equivalent.
  • Chemours Co (NYSE: CC) shares gained 6.2 percent to $22.53. Chemours will replace IDEXX Laboratories, Inc. (NASDAQ: IDXX) in the S&P MidCap 400 after the close of trading on January 4.
  • Nivalis Therapeutics Inc (NASDAQ: NVLS) shares rose 5.2 percent to $2.32. Nivalis Therapeutics disclosed that it is exploring strategic alternatives for the company and has engaged Ladenburg Thalmann to act as an advisor.
  • Abercrombie & Fitch Co. (NYSE: ANF) gained 5.1 percent to $12.73. FBR Capital upgraded Abercrombie & Fitch from Underperform to Market Perform.
  • Fusion Telecommunications Int'l, Inc. (NASDAQ: FSNN) surged 4.7 percent to $1.52. Craig-Hallum initiated coverage on Fusion Telecommunications with a Buy rating.
  • Global Blood Therapeutics Inc (NASDAQ: GBT) rose 4.2 percent to $14.90. JPMorgan initiated coverage on Global Blood Therapeutics with an Overweight rating.
  • Achaogen Inc (NASDAQ: AKAO) rose 4.1 percent to $13.53. Leerink Swann initiated coverage on Achaogen with an Outperform rating.
  • Aecom (NYSE: ACM) gained 3.4 percent to $38.26. Baird upgraded Aecom from Neutral to Outperform.

Latest Ratings for OREX

Mar 2016JMP SecuritiesDowngradesMarket OutperformMarket Perform
Feb 2016JP MorganDowngradesOverweightNeutral
Feb 2016RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for OREX
View the Latest Analyst Ratings


Related Articles (OREX + CBAY)

View Comments and Join the Discussion!

Posted-In: Mid-Day MoversNews Intraday Update Markets Analyst Ratings Movers

Latest Ratings

ANABHC Wainwright & Co.Initiates Coverage On43.0
MYCORoth CapitalInitiates Coverage On3.0
HUBGCowen & Co.Maintains83.0
FCFSCredit SuisseDowngrades83.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at